Advanced protein-based soluble activation enhances the quality and quantity of your next immunotherapy.
With our proprietary technology, we use CAR-T expansion to produce more clinically potent CAR-T cells reported to live longer in vivo and continue to deliver anti-cancer effects. Our product is efficient and effective, and uses less time and fewer T cells than competitor reagents.
CAR-T cells are the most clinically and commercially advanced of the anti-cancer cell therapies. While incredibly effective, they have faced multiple challenges, especially attributed to manufacturing. We at Nanotein work to address these challenges by greatly improving the quality and quantity of T cells produced.
Cancer cell therapies are the cancer treatment of the future. The foundation of CAR-T cell therapies is the T cells from which they are generated. The degree of stemness and overall quality of these cells are critical to CAR-T’s therapeutic success.
Up to 12 antibodies or cytokines of our choice can be conjugated to our central, proprietary, engineered protein-nanoparticle, enabling future novel product development.
We anticipate hiring in the near future. Check back in for current career opportunities.